Evotec wins grant to advance H3 receptor antagonist
pharmafile | May 4, 2010 | News story | Research and Development |Â Â CNS, Evotec, MSÂ
Evotec is to receive funding of up to 1.5 million euros from a German government fund to advance its H3 receptor antagonist programme into the clinic.
Using its CNS expertise coupled with its leading discovery platform, Evotec has identified and optimised H3 receptor antagonists through to pre-clinical development. This grant will help fund the programme through phase I trials.
The histamine H3 receptor is a drug target of high interest because of evidence that blocking this receptor in the brain can improve cognition, alertness and attention.
H3 receptor antagonists could become a new therapy class in a numerous CNS indications, including excessive fatigue associated with conditions such as multiple sclerosis.
Evotec won the grant as part of the Neu2 consortium, which focuses on developing drugs for multiple sclerosis and other neurodegenerative diseases.
Other consortium members includes Merck Serono, the European ScreeningPort, Bionamics, and the University Medical Center Hamburg-Eppendorf.
The grant was organised by Germany’s Federal Ministry of Education and Research (BMBF) to support innovative drug discovery programmes in the German pharma and biotech industry.
Related Content

Evotec and Bayer announce new kidney disease study
Evotec and Bayer have announced the initiation of a phase 2 clinical study in kidney …

Sanofi shares results from phase 2 trial for frexalimab in MS treatment
Sanofi has announced new phase 2 trial data for its CD40L monoclonal antibody, frexalimab, for …

Evotec shares progress in Bristol Myers Squibb neuroscience collaboration
Evotec has announced that it has reached important scientific progress within the neuroscience collaboration with …






